日本化学療法学会雑誌第50巻新薬特集号
|
|
|
- いとは さくいし
- 5 years ago
- Views:
Transcription
1 micafungin in vitro 3 3 micafungin Candida Aspergillus Candida albicans fluconazole Candida tropicalis, Candida glabrata, Candida krusei Aspergillus 90 MIC90 0. g ml amphotericin B fluconazole itraconazole Candida parapsilosis Candida guilliermondii MIC90 g ml Candida Aspergillus fumigatus Cryptococcus neoformans, Trichosporon Fusarium solani, Pseudallescheria boydii Candida A. fumigatus MIC ph MIC C. albicans Key words: micafungin in vitro Immunocompromised host 3 Immunocompromised host Candida Aspergillus Cryptococcus amphotericin B azole fluorocytosine FC Azole azole Candida albicans Candida 9 0 echinocandin anidulafungin LY 3033 pneumocandin caspofungin MK099 MIC MIC NCCLS MIC 9 Anidulafungin caspofungin MIC Candida Aspergillus 9 Micafungin Coleophoma empetri echinocandin FR Dglucan in vitro
2 Micafungin in vitro in vitro NCCLS I Micafungin amphotericin B ; Fungizone! fluconazole ; Diflucan! 0. itraconazole ; Itrizole! Cap.0 fluorocytosine FC; flucytosine C. albicans ATCC American Type Culture Collection IFM TIMM 3 FC 00 mg 00 ml dimethyl sulfoxide MIC MIC National Committee for Clinical Laboratory Standards NCCLS M A MIC RPMI 0 3 Nmorpholino propanesulfonic acid MOPS 0. M mol L ph.0 RPMI MOPS Sporothrix schenckii RPMI MOPS RPMI MOPS 9 00 L 3 Sabouraud dextrose agar SDA; glucose Bacto peptone. Bacto agar 3 Potato dextrose agar PDA 30 Dextrose Brain heart infusion agar BHIAS. schenckii 3 CO 3 Penicillium marneffei S. schenckii PDA 30 0 Coccidioides immitis Dextrose BHIA 3 00 L cells ml C. immitis cells ml Candida Saccharomyces cerevisiae, Cryptococcus neoformans, Trichosporon Aspergillus Pseudallescheria boydii 3 F. solani 30 3 C. immitis 3Sprothrix schenckii 3 CO MIC NCCLS M A 0 MIC MIC 0 MIC MIC Candida parapsilosis ATCC 09 Candida krusei ATCC C. albicans ATCC 900 MIC NCCLS M A. MIC C. albicans ATCC 900 C. parapsilosis ATCC 09 C. krusei ATCC Aspergillus fumigatus TIMM 003 MIC
3 Table Antifungal spectrum of micafungin Organism MIC Candida albicans ATCC 900 Candida albicans FP 33 Candida tropicalis TIMM 033 Candida glabrata ATCC Candida kefyr ATCC 3 Candida krusei ATCC Candida guilliermondii 3003 Candida parapsilosis ATCC 09 Candida stellatoidea IFM 9 Saccharomyces cerevisiae ATCC 93 Cryptococcus neoformans TIMM 03 Trichosporon cutaneum IFM 00 Trichosporon asahii TIMM Aspergillus fumigatus TIMM 003 Aspergillus niger ATCC Aspergillus nidulans IFM 39 Aspergillus flavus ATCC 93 Aspergillus terreus IFM 0 Aspergillus versicolor IFM 0 Fusarium solani IFM 3 Pseudallescheria boydii IFM Cladosporium trichoides IFM Exophiala dermatitidis IFM Exophiala spinifera ATCC Fonsecaea pedrosoi ATCC Absidia corymbifera IFM 0 Cunninghamella elegans IFO Rhizopus oryzae IFM 0 Rhizopus microsporus var. rhizopodiformis IFM Medium: RPMI 0 mm MOPS ph 0 Inoculum: 0 to 0 3 cells ml Culture: 3 30 days 3days more than days : micafungin, : fluconazole, : itraconazole, : amphotericin B cells ml 00 L ph RPMI 0 MOPS mol L mol L ph RPMI MOPS HSA RPMI MOPS 0..0 MFC MIC 00 L SDA 3 99 MFC MFC Candida A. fumigatus RPMI MOPS ml C. albicans FP 33 C. albicans ATCC 900 C. glabrata ATCC C. krusei ATCC C. parapsilosis ATCC 09 C. tropicalis TIMM 033 SDA 3 RPMI MOPS cells ml 3 ml RPMI MOPS control3
4 Micafungin in vitro Table MICs of micafungin against clinical isolates of yeasts Organism no of isolates Compound MIC range MIC0 b MIC90 b C. albicans C. albicans resistant C. tropicalis C. glabrata C. krusei 3 3 C. parapsilosis C. guilliermondii 9 C. neoformans 0 T. cutaneum Medium: RPMI 0 mm MOPS ph 0 Inoculum: 0 to 0 3 cells ml Culture: 3 days 3days todays b MIC0 or MIC90:TheMICsat which 0 or90 of isolates are inhibited, respectively : micafungin, : fluconazole, : itraconazole, : amphotericin B 3 9 RPMI MOPS C. albicans ATCC 900 SDA 30 RPMI MOPS cells ml ml ml MIC RPMI MOPS cells ml RPMI MOPS ml ml 3 II AMPH
5 Table 3 MICs of micafungin against clinical isolates of Aspergillus species Organism no of isolates Compound MIC range MIC0 b MIC90 b A. fumigatus A. niger A. flavus A. terreus Medium: RPMI 0 mm MOPS ph 0 Inoculum: cells ml Culture: 33 days b MIC0 or MIC90:TheMICsat which 0 or90 of isolates are inhibited, respectively : micafungin, : fluconazole, : itraconazole, : amphotericin B B Table Candida Saccharomyces cerevisiae, Aspergillus C. neoformans, Trichosporon F. solani, P. boydii MIC Candida C. neoformans Trichosporon cutaneum MIC Table C. albicans C. tropicalis, C. glabrata C. krusei 90 MIC90 0. ml C. parapsilosis C. guilliermondii MIC90 ml C. neoformans T. cutaneum MIC ml Aspergillus Aspergillus MIC Table 3 Aspergillus MIC ml 3 MIC Table Exophiala spinifera, Fonsecaea pedrosoi Cladosporium trichoides Table MICs of micafungin against dematiaceous fungi Organism MIC range Compound no of isolates E. dermatitidis E. spinifera F. pedrosoi C. trichoides Medium: RPMI 0 mm MOPS ph 0 Inoculum: cells ml Culture: 33 todays to0days : micafungin, : fluconazole, : itraconazole, : amphotericin B MIC 0. ml Exophiala dermatitidis 3 MIC ml 3 ml
6 Micafungin in vitro Table MICs of micafungin against dimorphic fungi Organism no of isolates: yeastlike form mycelial form Compound Yeastlike form MIC range Mycelial form H. capsulatum B. dermatitidis P. brasiliensis P. marneffei S. schenckii C. immitis b b b b Medium: RPMI 0 mm MOPS ph 0 Inoculum: Yeastlike form, 0 to 0 0 P. marneffei 0 0 3, S. schenckii 0 0 cells ml Mycelial form, 0 to 0 0 P. brasiliensis 0 0, C. immitis cells ml Culture: Yeastlike form 3 todays,aerobic culture S. schenckii,3 CO,withshaking Mycelial form, C. immitis,3 3 todays,aerobic culture b :Nottested : micafungin, : fluconazole, : itraconazole, : amphotericin B MIC Table H. capsulatum, B. dermatitidis, P. brasiliensis, P. marneffei S. schenckii H. capsulatum, B. dermatitidis, S. schenckii C. immitis MIC 0.00 ml AMPH B P. marneffei MIC ml AMPH B P. brasiliensis MIC ml 3. MIC ph HSA MIC Table Candida A. fumigatus MIC ph HSA MIC MFC Candida A. fumigatus MFC Table C. albicans C. albicans C. glabrata C. krusei MFC ml C. tropicalis C. guilliermondii MFC90 ml C. parapsilosis
7 Table Influence of culture conditions on MIC MIC Culture condition C. albicans ATCC 900 C. parapsilosis ATCC 09 C. krusei ATCC A. fumigatus TIMM 003 ph b Inoculum size c cells ml Addition of human serum d Addition of HSA d Culture : 3 days 3days b RPMI 0 mm MOPS was adjusted to a ph of,, and with mol L HClormol L NaOH,Inoculum size was cells ml c RPMI 0 mm MOPS ph 0 was used asatestmedium d RPMI 0 mm MOPS ph 0 was used as a test medium, inoculum size was cells ml MFC90 ml Candida MFC90 ml ml A. fumigatus MFC ml C. albicans FP 33 Fig 0.00 ml 99 3 ml 3 C. albicans C. glabrata, C. krusei, C. parapsilosis C. tropicalis Fig C. albicans C. glabrata C. krusei MIC 99C. parapsilosis C. tropicalis Candida MIC 3 9 Changes of viable counts log CFU Detection limit Drug concentrationg/ml : micafungin, : amphotericin B, : fluconazole : itraconazole Fig. Fungicidal activity against Candida albicans FP 33 after hours exposure. log CFU: logarithm of CFU after hours exposure logarithm of CFU at time zero C. albicans ATCC 900 MIC Fig 3 C. albicans FC 3
8 Micafungin in vitro Table MFCs of micafungin for clinical isolates of Candida species and Asperigillus fumigatus Organism no of isolates Compound MFC range MFC0 b MFC90 b C. albicans C. albicans resistant C. tropicalis C. glabrata C. krusei 0 C. parapsilosis 0 C. guilliermondii 0 A. fumigatus MFC: Minimum fungicidal concentration more than 99 of the original inoculum was killed Medium: RPMI 0 mm MOPS ph 0 Inoculum: 0 to 0 3 cells ml b MFC0 or MFC90:TheMFCsat which 0 or90 of isolates are inhibited, respectively : micafungin, : fluconazole, : itraconazole, : amphotericin B III in vitro NCCLS M A Candida MIC MIC M A 0 AMPH B MIC Candida in vitro C. albicans, C. tropicalis, C. glabrata C. krusei MIC90 C. albicans FC 3 FC C. parapsilosis C. guilliermondii MIC Candida 9 C. albicans FP 33 ATCC 900
9 C. albicans FP33 C. albicans ATCC900 Viable counts Log of cfu/ml 3 Viable counts Log of cfu/ml Time h Time h C. glabrata ATCC90030 C. krusei ATCC Viable counts Log of cfu/ml 3 Viable counts Log of cfu/ml Time h Time h C. parapsilosis ATCC09 C. tropicalis TIMM033 Viable counts Log of cfu/ml 3 Viable counts Log of cfu/ml Time h Time h : micafungin, : amphotericin B Fig. Timekill curve against Candida albicans FP 33 C. albicans ATCC 900 Candida glabrata ATCC Candida krusei ATCC Candida parapsilosis ATCC 09 and Candida tropicalis TIMM 033. ConcentrationsControl MIC MIC MICMICMIC C. albicans MFC90 C. albicans Candida MFC Candida MIC
10 Micafungin in vitro MICg/mL > Number of passage times -FC : micafungin, : amphotericin B, : fluconazole : itraconazole Fig 3. Change in the susceptibility of Candida albicans ATCC 900 to micafungin after repeated exposure to subinhibitory concentrations of. MIC A. fumigatus in vivo 3 3 A. fumigatus MIC Aspergillus MIC in vivo MIC M A Aspergillus MIC90 MIC C. neoformans, T. cutaneum, T. asahii, F. solani, P. boydii Aspergillus MIC caspofungin anidulafungin 9 H. capsulatum B. dermatitidis 3 C. immitis MIC H. capsulatum B. dermatitidis MIC P. brasiliensis MIC ml MIC ml P. marneffei S. schenckii MIC H. capsulatum B. dermatitidis 3 Dglucan FKS C. neoformans FKS C. neoformans 3 Dglucan 3 Dglucan chitin chitosan 3 Dglucan 3 Dglucan F. solani, P. boydii B. dermatitidis P. brasiliensis glucan glucan in vivo MIC MIC MIC 3 Candida Aspergillus Anaissie E: Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis : S 3 S3 99 Hadley S Karchmer A W: Fungal infections in solid
11 organ transplant recipients. Infect Dis Clin N Am 9: Dixon D M McNeil M M Cohen M L et al.: Fungal infections: a growing threat. Public Health Re : 3 99 Morrison V A Haake R J Weisdorf D J: The spectrum of non Candida fungal infections following bone marrow transplantation. Medicine : Padhye A A Hampton A A Hampton M T et al.: Chromoblastomycosis caused by Exophiala spinifer Clin Infect Dis : Patterson T F Andriole V T Zervos M J et al.: The epidemiology of pseudallescheriasis complicating transplantation : nosocomial and community acquired infection. Mycoses 33: Singh N Chang F Y Gayowski T et al.: Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis : Thomas A H: Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N substituted imidazoles. J Antimicrob Chemother : Hitchcock C A Pye G W Johnson E M et al.: Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 3: Debono M Gordee R S: Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol : 9 99 Vazquez J A Lynch M Sobel J D: In vitro activity of a new pneumocandin antifungal agent L 33 0 against azolesusceptible and resistant Candida and Torulopsis species. Antimicrob Agents Chemother 39: Verweij P E Oakley K L Morrissey J et al.: Efficacy of LY 3033 against amphotericin B susceptible and resistant Aspergillus fumigatus in amurine model of invasive aspergillosis. Antimicrob Agents Chemother : Petraitis V Petraitiene R Groll A H et al.: Antifungal efficacy safety and singledose pharmacokinetics of LY 3033 a novel echinocandin B in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother : Bartizal K Gill C J Abruzzo G K et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK099 L3 Antimicrob Agents Chemother : National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M A. National Committee for Clinical Laboratory Standards Wayne Pa., 99 Krishnarao T V Galgiani J N: Comparison of the in vitro activities of the echinocandin LY 3033 the pneumocandin MK099 and fluconazole against Candida Species and Cryptococcus neoformans Antimicrob Agents Chemother : Ingroff A E: Comparison of in vitro activities of the new triazole SCH 9 and the echinocandins MK 099 L3 and LY 3033 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 3: Poeta M D Schell W A Perfect J R: In vitro antifungal activity of pneumocandin L3 against a variety of clinically important molds. Antimicrob Agents Chemother : Zhanel G G Karlowsky J A Harding G A J et al.: In vitro activity of a new semisynthetic echinocandin LY3033 against systemic isolates of Candida species Cryptococcus neoformans, Blastomyces dermatitidis,and Aspergillusspecies. Antimicrob Agents Chemother : Iwamoto T Fujie A Sakamoto K et al.: WF 99 A B and C novel antifungal lipopeptides I. Taxonomy fermentation isolation and physico chemical properties. J Antibiotics : Tomishima M Ohki H Yamada A et al.: FK 3 a novel watersoluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiotics : 999 : Micafungin Candida albicans Aspergillus fumigatus 0 S : Abruzzo G K Flattery A M Gill C J et al.: Evaluation of the echinocandin antifungal MK099 L3 : efficacies in mouse models of disseminated aspergillosis candidiasis and cryptococcosis. Antimicrob Agents Chemother : Kurtz M B Bernard E M Edwards F F et al.: Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemothe. 39: 9 99 Oakley K L Moore C B Denning D W: In vitro activity of the echinocandin antifungal agent LY in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother : Thompson J R Douglas C M Li W et al.: A glucan synthase FKS Homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol : SietsmaJH Wessels J G H: Apical wall biogenesis. The Mycota I Growth Differentiation and sexuality Wessels J G H Meinhardt F edsp. SpringerVerlag Berlin 99 Domer J E: Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidis JBacteriol 0: Kanetsuna F Carbonell L M: Cell wall glucans of the yeast and mycelial forms of Paracoccidioides brasiliensis JBacteriol 0: Kanetsuna F Carbonell L M: Cell wall composition of the yeastlike and mycelial forms of Blastomyces
12 Micafungin in vitro dermatitidis JBacteriol 0: 9 9, 9 3 Kanetsuna F Carmonell L M Azuma I et al.: Biochemical studies on the thermal dimorphism of Paracoccidioides brasiliensis J Bacteriol 0: Maresca B Kobayashi G S: Dimorphism in Histoplasma capsulatum: amodelforthestudyofcell differentiation in pathogenic fungi. Microbiol Rev 3: SanBlas G: The cell wall of fungal human pathogens: its possible role in hostparasite relationships. Mycopathologia 9: : micafungin in vitro 0 S : 9 00 In vitro activity of a new lipopeptide antifungal agent micafungin against a variety of clinically important fungi Fumiaki Ikeda Kazumi Otomo Tohru Nakai Yoshihiko Morishita Katsuyuki Maki Shuichi Tawara Seitaro Mutoh Fumio Matsumoto and Shogo Kuwahara 3 Medicinal Biology Research Laboratories Fujisawa Pharmaceutical Co., Ltd., KashimYodogawaku Osaka 3 Japan Kanagawa Prefectural Nursing and Hygienic School Hospital 3 Toho University School of Medicine The in vitro antifungal activity and spectrum of micafungin were compared with those of amphotericinb fluconazole and itraconazole using a broth microdilution method as specified by the National Committee for Clinical Laboratory Standards NCCLS document M A. exhibited broadspectrum activity against clinically important pathogens including Candida species and Aspergillus species and its MIC90 levels against C. albicans including resistant C. albicansc. tropicalis, C. glabrata, C. krusei and Aspergillus species were 0. ml which were lower than those for the other antifungal agents tested. The MIC90 levels of against C. parapsilosis and C. guilliermondii were and ml respectively which were comparable to orhigher than those for the other antifungal agents tested. exhibited concentrationindependent fungicidal activity at concentrations higher than the MIC against most Candida species. In contrast the MFCs of against A. fumigatus isolates were much higher than the MICs of the other agents indicating that its action is fungistatic against this species. showed moderate to weak activity against most dematiaceous fungi and had no activity against Cryptococcus neoformans, Trichosporon species Fusarium solani, Pseudallesheria boydii and zygomycetes. Although showed potent activity against the mycelial form of dimorphic fungi it had weak or no activity against their yeastlike form. Neither the ph of the test medium nor the inoculum size greatly affected the MIC values of while addition of human serum or human serum albumin increased the MIC values against Candida species and A. fumigatus In experiments on resistance induction the MIC of for C. albicans was not significantly changed; indicating that there is a low probability of induced resistance.
Key words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
VOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
Key words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant
Key words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant Fig. 1 Annual changes in percentages of fungi isolated from blood and vascular catheters Fig. 2 Frequencies of fungi
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
山口英世先生
Laboratory diagnosis of imported mycoses : how to safely execute laboratory examinations Hideyo YAMAGUCHI 5 1 6 1 1976 7 019-0395 359 Teikyo University Institute of Medical Mycology (TIMM) (359 Otsuka,
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
CHEMOTHERAPY FEB. 1994
CHEMOTHERAPY FEB. 1994 CHEMOTHERAPY FEB. 1994 Table 1. In vitro effect of flucytosine combined with fluconazole on Candida app. Fig. 1. Chemotherapeutic effect of combinations of flucytosine and uconazole
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
日本化学療法学会雑誌第50巻新薬特集号
Micafungin Candida albicans Aspergillus fumigatus 1 1 1 2 2 2 2 2 1 2 Micafungin MCFG Candida albicans Aspergillus fumigatus MCFG C. albicans ATCC 90028 A. fumigatus TIMM 0063 1 3 D glucan C. albicans
Key words: Surfactant, Tween, Legionella
Key words: Surfactant, Tween, Legionella Fig. 1 Inhibitory Activity of Various Tween Against Legionella pneumophila Fig. 2 Inhibitory Activity of Various Tween Against Legionella bozemanii Fig. 3 Inhibitory
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
感染症学雑誌第80巻第6号
Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ
日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
ひとくちメモ/山口英世先生
Epidemiology of antifungal resistance : current status and future perspective Hideyo YAMAGUCHI 2 4 6 4 9 4 MCZ MCFG 7 4 MRSA Candida spp. MCZ a B b MCFG P45 4αCYP5 c DNA d CYP5 CYP5,3-D-,3-D-,3-D- a b
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I
Feb. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 37 37 Liposomal amphotericin B 1 2 2 2 1 1 1 2 1 1 2 2012 12 25 33 Lymphangioleiomyomatosis: LAM 2 20xx 1 CT Aspergillus spp. Micafungin MCFG Itraconazole
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
A A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114
Visual Evaluation of Polka-dot Patterns Yoojin LEE and Nobuko NARUSE * Granduate School of Bunka Women's University, and * Faculty of Fashion Science,
Visual Evaluation of Polka-dot Patterns Yoojin LEE and Nobuko NARUSE * Granduate School of Bunka Women's University, and * Faculty of Fashion Science, Bunka Women's University, Shibuya-ku, Tokyo 151-8523
Pseudomonas aeruginosa S-827 Fig. 1. Method of biofilm formation. Table 1. Susceptibilities of antimicrobial agents on agar plate and in broth against Pseudomonas aeruginosa S-827 JULY CHEMOTHERAPY 888
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
CHEMOTHERAPY SEPT Amphotericin B (AMPH-B), flucytosine (5- SDA PDA Procedure for disk method 1. Prepare agar plates containing two-fold dilution
CHEMOTHERAPY SEPT. 1993 Amphotericin B (AMPH-B), flucytosine (5- SDA PDA Procedure for disk method 1. Prepare agar plates containing two-fold dilutions of drugs and dry agar surface at room temperature
Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho
Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical School While the problem of late pregnant hypertension
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (<400/ml) before candidemia AMoL; acute monocytic leukemia VH; intravenous yperali
Key words: candidemia, HA-test, Cand-Tec, D-arabinitol, Ĉ-d-glucan Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (
05-d m-4.03
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 51(51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 9 2004 3 6 4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS
Mikio Yamamoto: Dynamical Measurement of the E-effect in Iron-Cobalt Alloys. The AE-effect (change in Young's modulus of elasticity with magnetization
Mikio Yamamoto: Dynamical Measurement of the E-effect in Iron-Cobalt Alloys. The AE-effect (change in Young's modulus of elasticity with magnetization) in the annealed state of iron-cobalt alloys has been
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
(1) Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M and Kuroda M: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,
日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004
The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
VOL. 36 S-3 CHEMOTHERAPY 437
VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates
semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG
CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
2 CHEMOTHERAPY JAN. 1976 VOL. 24 NO. 1 CHEMOTHERAPY 3 Table 1 Antibacterial spectra of Cephacetrile, Cephalothin, Cephaloridine and Cefazolin 4 CHEMOTHERAPY JAN. 1976 Fig. 1 In vitro activity of Cephacetrile,
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia